158873-14-4 Usage
Description
(N-ME-D-PHE7)-BRADYKININ, a synthetic peptide derived from bradykinin, is a potent agonist for the B1 receptor. It is characterized by its ability to induce vasodilation, hypotension, and smooth muscle contraction, as well as its involvement in pain sensation and inflammation. This chemical is widely utilized in research to study the physiological effects of bradykinin and its related peptides, making it a valuable tool in the field of pharmacology.
Uses
Used in Pharmaceutical Research:
(N-ME-D-PHE7)-BRADYKININ is used as a research compound for investigating the physiological effects of bradykinin and its related peptides. Its agonist properties for the B1 receptor make it a crucial tool in understanding the mechanisms of vasodilation, hypotension, and smooth muscle contraction.
Used in Drug Development for Medical Conditions:
(N-ME-D-PHE7)-BRADYKININ is used as a potential therapeutic agent for conditions such as diabetes, hypertension, and asthma. Its ability to induce vasodilation and modulate pain sensation and inflammation makes it a promising candidate for the development of new treatments for these medical conditions.
Used in Drug Delivery Systems:
In the field of drug delivery, (N-ME-D-PHE7)-BRADYKININ can be employed as a component in the development of novel drug delivery systems. These systems aim to enhance the delivery, bioavailability, and therapeutic outcomes of the peptide by utilizing various carriers, such as organic and metallic nanoparticles.
Check Digit Verification of cas no
The CAS Registry Mumber 158873-14-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,8,8,7 and 3 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 158873-14:
(8*1)+(7*5)+(6*8)+(5*8)+(4*7)+(3*3)+(2*1)+(1*4)=174
174 % 10 = 4
So 158873-14-4 is a valid CAS Registry Number.
158873-14-4Relevant articles and documents
Highly selective bradykinin agonists and antagonists with replacement of proline residues by N-methyl-D- and L-phenylalanine
Reissmann, Siegmund,Schwuchow, Carola,Seyfarth, Lydia,De Castro, Luis Felipe Pineda,Liebmann, Claus,Paegelow, Inge,Werner, Heinz,Stewart, John M.
, p. 929 - 936 (1996)
For further studies on the structural and conformational requirements of positions 2, 3, and 7 in the bradykinin sequence, we replaced the proline residues by the more hydrophobic and conformationally restricted N-methyl-L- and D-phenylalanine (NMF). The biological activities of the new analogs were evaluated on rat uterus, guinea pig ileum, and guinea pig lung strip. Receptor binding of the analogs was studied in membranes from rat uterus and guinea pig ileum. Influence of bradykinin analogs on the release of cytokines from mouse spleen cell cultures was also measured. Bradykinin analogs were synthesized by the solid phase method, using Boc strategy on PAM or Merrifield resins. The best results in the formation of the N-methylamide bond were obtained with the coupling reagent PyBrop. In position 7 the substitution of D-Phe by D-NMF, retaining the configuration of the amino acid, converts bradykinin antagonists into agonists. The bradykinin analogs with D-NMF at position 7 gave the highest known tissue selectivity for rat uterus among agonists. [L-NMF2]bradykinin has moderate agonist activity on rat uterus but antagonist activity on guinea pig lung strip. It represents a new antagonist for B2 receptors without any replacement at position 7. The same analog completely inhibits bradykinin-evoked cytokine expression by mononuclear cells.
